Can bortezomib (Velcade) be administered weekly instead of the standard twice‑weekly schedule in a daratumumab‑VRD regimen?

Weekly Bortezomib Administration in Daratumumab-VRD Regimens

Yes, bortezomib can be administered weekly in daratumumab-VRD regimens, and this approach is both effective and preferred to reduce peripheral neuropathy risk. 1, 2

Standard Dosing Schedule for Daratumumab-VRD

When combining daratumumab with VRD, the regimen typically uses 4-week cycles rather than the traditional 3-week VRD cycles 3:

Cycle 1 Bortezomib Schedule (Intensive Phase)

• Bortezomib 1.3 mg/m² subcutaneously on days 1,4,8, and 11 of the first 4-week cycle 3, 4
• This twice-weekly schedule is maintained throughout the first cycle when combined with daratumumab 3
• After cycle 1, the schedule can be modified to weekly dosing 5, 6

Weekly Bortezomib Modifications

Weekly bortezomib (days 1,8,15) is the preferred schedule after initial cycles for the following reasons 1:

• Comparable efficacy: Multiple real-world studies demonstrate that once-weekly bortezomib achieves similar overall response rates (ORR), progression-free survival (PFS), and overall survival (OS) compared to twice-weekly dosing 7, 2
• Reduced neuropathy: Weekly dosing significantly decreases peripheral neuropathy rates (18.5% vs 34.7% with twice-weekly) 2
• Better tolerability: Fewer dose reductions required and lower rates of grade 3/4 adverse events (37%/3% vs 48%/12%) 1

Evidence Supporting Weekly Dosing

Real-World Effectiveness Data

• A 2024 analysis of 2,497 US patients showed no difference in median PFS (37.2 months with weekly vs 39.6 months with twice-weekly, p=0.906) or OS between schedules 2
• Weekly bortezomib use has increased from 57.7% in 2017 to 73.1% in 2022, reflecting clinical preference 2
• In the GRIFFIN trial using daratumumab-RVD, bortezomib was administered subcutaneously on days 1,4,8, and 11 during induction, demonstrating that this schedule is effective when combined with daratumumab 5

Specific Regimen Considerations

When using daratumumab with VRD 3, 4:

• Lenalidomide: 25 mg orally days 1-14 of each 4-week cycle
• Dexamethasone: Either 20 mg on the day of and day after each bortezomib dose, OR 40 mg on days 1,8,15,22
• Daratumumab: 16 mg/kg IV weekly (cycles 1-2), every 2 weeks (cycles 3-6), then every 4 weeks 4

Clinical Implementation Algorithm

For newly diagnosed patients starting daratumumab-VRD 3, 5, 6:

1. Cycles 1-4 (Induction): Consider twice-weekly bortezomib (days 1,4,8,11) for maximum initial disease control 3, 5
2. Cycles 5 onward: Transition to weekly bortezomib (days 1,8,15) to minimize cumulative neuropathy risk 1, 7
3. For patients with pre-existing neuropathy or high neuropathy risk: Start with weekly dosing from cycle 1 1

For relapsed/refractory patients 8, 9:

• Weekly bortezomib is standard and effective, with 82% ORR and median PFS of 16 months in real-world UK data 8
• Grade 2-3 peripheral neuropathy rate was only 7% with weekly dosing 8

Important Caveats

Route of Administration

• Subcutaneous administration is strongly preferred over intravenous for bortezomib, as it provides noninferior efficacy with significantly reduced peripheral neuropathy 1

High-Risk Patients

• Patients with high-risk cytogenetics, ISS stage III, or extramedullary disease have inferior outcomes even with daratumumab-containing regimens 8
• These patients may benefit from the more intensive twice-weekly schedule initially, followed by transition to weekly dosing 8

Monitoring Requirements

• Herpes zoster prophylaxis is mandatory for all patients receiving proteasome inhibitors 10
• Close monitoring for cardiac, renal, and pulmonary toxicities is required when carfilzomib is used instead of bortezomib 1